Urinary Tract Infections
Adding enzyme therapy to the antibiotic therapy dramatically shortens the
time that it takes both feel better, and for lab tests to
show a decrease in the systemic inflammation that
accompanies a urinary tract infection. This has been
observed in the recurrent urinary tract infections – which
have traditionally been very hard to treat –even with
antibiotics and other drugs.
Keep in mind, these recurrent urinary tract infections are
notorious for being hard to treat and hard to keep coming
back. The fact that we can use Wobenzym to make antibiotics
more effective – and to prevent re-infection – is a very
important point.
When we use Wobenzym to make antibiotic more effective we
are using the adjuvant properties of Wobenzym. An adjuvant
is a substance that significantly improves the effective of
other therapies that have limited effectiveness. Wobenzym
has been used as an adjuvant to treat a number of
inflammatory and infectious diseases. This hold true for not
only recurrent urinary tract infections and pyelonephritis,
but also for recurrent respiratory tract infections, as well
as chronic infections of the reproductive system.
From FREQUENTLY ASKED
QUESTIONS, with answers by Joseph J Collins, RN, ND
Read the special section:
KIDNEY AND BLADDER CONDITIONS & WOBENZYM®
What the literature says about Systemic Enzyme Support and:
Phlogenzym® in patients with relapsing urinary
tract infections.
Schlüter. P.
Phlogenzym® in patients with relapsing urinary tract infections:
Efficacy & Tolerance. Schlüter. Gartenstraße 96, D-69502 Hemsbach,
Germany. Report by: MUCOS Pharma GmbH & Co, Abt. Klinische Forschung,
Kirchplatz 8, D-82538 Geretsried, Germany
Summary:
Efficacy and tolerance of the enzyme combination preparation
Phlogenzym® were tested in a randomized double blind clinical phase
III (acc. to German drug law) trial with two paralIel groups in
patients with relapsing urinary tract infections (UTI) as compared
with placebo.
Forty (40) patients with the typical symptoms of UTI (as
pollakisuria, nycturia, dysuria, imperative strangury, painful
micturition and suprapubic pain) were taken into this study.
All 40 patients received an antibacterial therapy during the first
week. Twenty (20) patients took the test preparation Phlogenzym® and
another 20 patients got placebo: each two tablets t.i.d. of the
active or the placebo drug, resp., for three weeks. The data of all
40 patients were evaluable.
The primary investigator was Peter Schlüter. M.D., Gartenstrasse 16,
D-69502 Hemsbach, Germany.
At baseline, the groups were comparable with regard to age, sex,
height and weight, and the six symptoms of UTI mentioned above (p >
.05 in Wilcoxon- Mann-Whitney-U-test).
A sum score of the six clinical symptoms was defined as main
endpoint for efficacy. Secondary criteria were urinalysis, blood
picture and serum diagnosis, and global judgement of efficacy by
physician and patients.
The main endpoint "sum score" showed a statistically significant
superiority (p < .0001 ) in favor of Phlogenzym® at days 3, 7, and
14.
The inflammation was healed in all patients at day 14 in the
Phlogenzym® group, whereas some patients still had UTI at day 14 and
even day 21 in the placebo group.
Laboratory values from urinalysis, typical for UTI normalized
earlier in the Phlogenzym® group, with several significant
differences (p < .05).
Improvement of ESR and reduction of leucocytes in the blood
correlated with the decrease of inflammation.
Physician and patients judged the efficacy of Phlogenzymâ
significantly superior to that of placebo (p < .0001, and p = .0002,
resp.).
The tolerance was excellent, as seen from the global judgement of
tolerance by physician and patients, as well as from the complete
lack of unwanted side effects.
Poster Reference Number 32.